Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
Dorine Fournier, S. Jouneau, Guillaume Bouzillé, Élisabeth Polard, Marie‐Noëlle Osmont, Lucie‐Marie Scailteux
Topics & Concepts
PirfenidoneNintedanibMedicineIdiopathic pulmonary fibrosisIncidence (geometry)Adverse drug reactionInternal medicineAdverse effectGastroenterologyDrugPharmacologyLungOpticsPhysicsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Treatments and MutationsChronic Myeloid Leukemia Treatments